Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study

Affiliations

• ¹ Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
• ² Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN, USA.
• ³ Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
• ⁴ Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
• ⁵ Department of Hematology and Oncology, Baptist Health Medical Group, Lexington, KY, USA.
• ⁶ Department of Radiation Oncology, MetroHealth Medical Center, Cleveland, OH, USA.
• ⁷ Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
• ⁸ Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
• ⁹ Precision Oncology Program, Saint Luke's Cancer Institute, Kansas City, MO, USA.
• ¹⁰ Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
• ¹¹ US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA.
• ¹² Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.
• ¹³ Global Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA.